(Q36180883)

12 August 2017

1 reference

title

Inflammation and the etiology of type 2 diabetes (English)

1 reference

12 August 2017

0 references

Ake Sjöholm

1

1 reference

12 August 2017

Thomas Nyström

series ordinal

2

1 reference

12 August 2017

publication date

1 January 2006

1 reference

Diabetes - Metabolism: Research and Reviews

12 August 2017

published in

1 reference

12 August 2017

volume

22

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

4-10

1 reference

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

12 August 2017

cites work

1 reference

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

Clinical significance of pleiotropic effects of statins: lipid reduction and beyond

21 January 2018

1 reference

C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?

21 January 2018

1 reference

Global and societal implications of the diabetes epidemic

21 January 2018

1 reference

7 January 2021

Treating type 2 diabetes - today's targets, tomorrow's goals

1 reference

7 January 2021

Inflammation: the link between insulin resistance, obesity and diabetes

1 reference

7 January 2021

A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis

1 reference

7 January 2021

The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes

1 reference

7 January 2021

Atherothrombosis, inflammation, and diabetes

1 reference

7 January 2021

Inflammation and Insulin Resistance

1 reference

7 January 2021

Adipocytokines and insulin resistance

1 reference

7 January 2021

Insulin resistance and chronic cardiovascular inflammatory syndrome

1 reference

7 January 2021

Do atherosclerosis and type 2 diabetes share a common inflammatory basis?

1 reference

7 January 2021

Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study

1 reference

7 January 2021

C-reactive protein as a predictor for incident diabetes mellitus among middle-aged men: results from the MONICA Augsburg cohort study, 1984-1998.

1 reference

7 January 2021

Elevated C-Reactive Protein Is a Risk Factor for the Development of Type 2 Diabetes in Japanese Americans

1 reference

7 January 2021

Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.

1 reference

7 January 2021

Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study

1 reference

7 January 2021

C-Reactive Protein Is Independently Associated With Fasting Insulin in Nondiabetic Women

1 reference

7 January 2021

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

1 reference

7 January 2021

C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study

1 reference

7 January 2021

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

1 reference

7 January 2021

Is type II diabetes mellitus a disease of the innate immune system?

1 reference

7 January 2021

Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance

1 reference

7 January 2021

Activation of the hypothalamic-pituitary-adrenal axis in obesity: cause or consequence?

1 reference

7 January 2021

Differential effects of cytokines on long-term mitogenic and secretory responses of fetal rat pancreatic beta-cells

1 reference

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

7 January 2021

Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD).

1 reference

7 January 2021

Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study

1 reference

7 January 2021

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme

1 reference

7 January 2021

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

1 reference

7 January 2021

Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).

1 reference

7 January 2021

VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk

1 reference

7 January 2021

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

7 January 2021

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

7 January 2021

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

7 January 2021

Anti-inflammatory and immunomodulating properties of statins. An additional tool for the therapeutic approach of systemic autoimmune diseases?

1 reference

7 January 2021

Modulation of the inflammatory process by statins

1 reference

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

7 January 2021

Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells

1 reference

7 January 2021

Prevention of primary nonfunction of canine islet autografts by treatment with pravastatin

1 reference

7 January 2021

1 reference

7 January 2021

Peroxisome proliferator-activated receptors in inflammation control

1 reference

7 January 2021

Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone

1 reference

7 January 2021

Inhibition of tumor necrosis factor-alpha with anti-diabetic agents

1 reference

7 January 2021

Hypothesis: PGE, Carbohydrate Homeostasis, and Insulin Secretion: A Suggested Resolution of the Controversy

1 reference

7 January 2021

Prostaglandins, Glucose Homeostasis, and Diabetes Mellitus

1 reference

7 January 2021

Prostaglandins inhibit pancreatic beta-cell replication and long-term insulin secretion by pertussis toxin-insensitive mechanisms but do not mediate the actions of interleukin-1 beta

1 reference

7 January 2021

Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta

1 reference

7 January 2021

Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis

1 reference

7 January 2021

Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease

1 reference

7 January 2021

Minireview: Adiposity, Inflammation, and Atherogenesis

1 reference

7 January 2021

Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women

1 reference

7 January 2021

Beyond blood pressure: the endothelium and atherosclerosis progression

1 reference

7 January 2021

Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: evidence of an antiinflammatory action

1 reference

7 January 2021

Angiotensin blockade prevents type 2 diabetes by formation of fat cells

1 reference

7 January 2021

Identifiers

DOI

10.1002/DMRR.568

1 reference

12 August 2017

1 reference